B-lymphocyte stimulator (BLyS) -specific inhibitor (Belimumab)

Abstract

Belimumab, a human monoclonal antibody that inhibits the B-lymphocyte stimulator (BLyS), was the first biologic agent approved for treatment of systemic lupus erythematosus (SLE). Elevated serum BLyS levels are observed in patients with SLE. Belimumab inhibits the biological activity of BLyS, which is important for the survival and development of B lymphocytes into antibody-producing mature plasma B cells. Belimumab is indicated for treatment of patients with active SLE receiving standard therapy, such as glucocorticoids and immunosuppressants. The efficacy of belimumab remains unclear in patients with severe active lupus nephritis in Japan. However, in other countries, the combined use of belimumab as initial and/or maintenance therapy is recommended considering its additional benefit in cases of lupus nephritis. Belimumab is a useful biologic agent to achieve dose reduction or enable discontinuation of glucocorticoids in the management of SLE. Future studies should investigate the appropriate timing for the introduction of this useful drug.